[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545997":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":43,"responsibleParty":61,"collaborators":32,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":32,"eligibilityCriteria":68,"healthyVolunteers":65,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":32,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":46,"whyStopped":32,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Affiliated Hospital of Nantong University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Pretreatment with an autophagy inhibitor (HCQ) before chemotherapy and radiotherapy","EXPERIMENTAL","Hydroxychloroquine (HCQ), is used one day before chemotherapy and radiotherapy, 400-600mg, oral tablet, once. During chemotherapy and radiotherapy, HCQ maintenance dose is 200-400mg daily.",[13],"Drug: HCQ",{"label":15,"type":16,"description":17,"interventionNames":18},"Receive placebo before and during chemotherapy and radiotherapy","PLACEBO_COMPARATOR","Placebos are used one day before chemotherapy and radiotherapy, and during the therapy.",[19],"Other: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","HCQ","HCQ, 400-600mg, oral tablet, once, one day before chemotherapy and radiotherapy. During therapy, HCQ maintenance dose is 200-400mg daily.",[9],[27],"Hydroxychloroquine",{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","Placebo, oral tablet, once, one day before chemotherapy and radiotherapy. During therapy, placebo maintenance oral tablet once daily.",[15],null,[34],{"name":35,"affiliation":36,"role":37},"Bo You, Doctor","Department of Otorhinolaryngology-Head and Neck Surgery, Affiliated Hospital of Nantong University","PRINCIPAL_INVESTIGATOR",[39],{"name":35,"role":40,"phone":41,"phoneExt":41,"email":42},"CONTACT","+8615851358688","youbo19891014@163.com",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Bo You","RECRUITING","Nantong","Jiangsu","226000","China","CN",{"type":53,"coordinates":54},"Point",[55,56],120.87472,32.03028,{"lat":56,"lon":55},[59],{"name":45,"role":40,"phone":32,"phoneExt":32,"email":60},"youbo@ntu.edu.cn",{"type":62,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100545997","pretreatment-with-hcq-before-radiotherapy-and-chemotherapy-in-advanced-npc-patients-100545997",false,"NCT06389201","Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients","Inclusion Criteria:\n\n* Clinical diagnosis of NPC.\n* Have not received any cancer therapies\n* Must provide informed consent\n\nExclusion Criteria:\n\n* With metastasis before the first treatment.","ALL","20 Years","70 Years",{"count":73,"type":74},30,"ESTIMATED","INTERVENTIONAL",[77],"NA","Dormant cancer cells that survive anti-cancer therapy can lead to cancer recurrence and disseminated metastases that prove fatal in most cases. Recently, specific dormant polyploid giant cancer cells (PGCC) have drawn the investigators' attention because of their association with the clinical risk of nasopharyngeal carcinoma (NPC) recurrence, as demonstrated by previous clinical data. In study, the investigators report the biological properties of PGCC, and reveal that autophagy is a critical mechanism of PGCC induction. Moreover, pharmacological inhibition of autophagy greatly impaired PGCC formation, significantly suppressing metastasis and improving survival in a mouse model. Mechanistically, chemotherapeutic drugs partly damaged mitochondria, and activated autophagy to promote PGCC formation. High numbers of PGCCs correlated with shorter recurrence time and worse survival outcomes in NPC patients. Collectively, these findings suggest a therapeutic approach of targeting dormant PGCCs in cancer.\n\nPretreatment with an autophagy inhibitor (HCQ) before chemotherapy and radiotherapy could prevent formation of therapy-induced dormant polyploid giant cancer cells, thereby reducing recurrence and metastasis of nasopharyngeal carcinoma.",[80],"Nasopharyngeal Carcinoma",[82,83,84,85,86],"autophagy","tumor dormancy","nasopharyngeal carcinoma","recurrence","metastasis","2025-02-14",{"date":89,"type":90},"2025-02-18","ACTUAL",{"date":92,"type":90},"2024-08-01",{"date":94,"type":74},"2034-08-01",{"name":5,"class":6},1]